Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug1363	IP-10 in CDS protocol Wiki	1.00
drug131	Acalabrutinib Wiki	0.50

Correlated MeSH Terms (2)

---

	Name (Synonyms)	Correlation
D003141	Communicable Diseases NIH	0.08
D007239	Infection NIH	0.05

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Assessment of AUCinf for acalabrutinib and ACP-5862 (metabolite of acalabrutinib) following administration of capsule with and without rabeprazole.

Measure: Area under plasma concentration-time curve from time zero to infinity (AUCinf)

Time: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2

---

Description: Assessment of AUClast for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.

Measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)

Time: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2

---

Description: Assessment of Cmax for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.

Measure: Maximum observed plasma concentration (Cmax)

Time: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2

---

Secondary Outcomes

Description: Assessment of the safety and tolerability of acalabrutinib capsule when administered with COCA-COLA and rabeprazole.

Measure: Number of participants with adverse events and serious adverse events

Time: From screening until Follow-up visit (Upto 5 to 6 Weeks)

---